Christopher Posner, President & CEO, LEO Pharma Inc. - Region U.S.

Chris Posner joined LEO Pharma in July 2017 as LEO Pharma’s Executive Vice President of Region US and President & CEO of LEO Pharma Inc. – the U.S. affiliate.  Mr. Posner leads the LEO U.S. Leadership Team and is a member of LEO Pharma’s Global Leadership Team. 
Mr. Posner joined LEO Pharma from R-Pharm US, a specialty pharmaceutical start-up focused on oncology and chronic immune diseases, where he was the Head of Worldwide Commercial Operations. Mr. Posner has wide-ranging experience in the pharma industry including biologic medicines and immunology from leading the commercialization of US and global brands at Bristol-Myers-Squibb, Pfizer, Wyeth, Endo and Merck & Co. Before joining the pharmaceutical industry , Mr. Posner was a senior economic consultant at the Wharton Econometrics Forecasting Associates.
Mr. Posner earned his MBA from Fuqua School of Business, Duke University and his BA in Economics from Villanova University.

Judit H. Nyirady, Vice President, Medical Strategy & Scientific Affairs

Dr. Judit Nyirady joined LEO Pharma Inc. in May 2017 as the Vice President of Medical Strategy & Scientific Affairs.  Dr. Nyirady is responsible for the medical and scientific affairs strategies for LEO Pharma U.S., as well as the U.S. Quality, Pharmacovigilance, Drug Safety and Medical Information functions.  

Prior to joining LEO, Dr. Nyirady worked at Novartis as interim Medical Unit  Head of Dermatology & Immunology - U.S. Clinical Development & Medical Affairs, and Executive Director of Dermotology in U.S. Clinical Development & Medical Affairs.  Before joining Novartis, Dr. Nyirady worked at Johnson & Johnson Consumer Products Worldwide in Medical Affairs - Dermatology.

Dr. Nyirady holds a M.B.A. from Cornell University, Johnson Graduate School of Management and obtained her medical degree in Hungary from Albert Szent-Gyorgyi Medical University. 

Keith Bernius, Vice President, Finance

Keith Bernius joined LEO Pharma Inc. in April 2014 as the Vice President, Finance.  Mr. Bernius is responsible for the overall management of the U.S. Finance function with responsibility of business finance, accounting & tax, contract & pricing, trade and supervision of IT and procurement activities.    

Prior to joining LEO,  Mr. Bernius  was the Vice President of Finance and Treasurer of Altegrity Inc. in NYC where he has been responsible for global treasury, investor relations, risk management, enterprise FP&A and real estate.  Prior to Altegrity, he worked at Alpharma Pharmaceuticals for seven years serving in both corporate finance and divisional roles.  In his last position at Alpharma as Vice President, Finance and Pharmaceuticals CFO, Mr. Bernius was responsible for finance, trade and commercial operations functions. 

Mr. Bernius holds a Bachelor of Science Degree in Accounting from Manhattan College and is a Certified Public Accountant.


Mitch Johnson, VP, Sales

Mitchell (Mitch) Johnson joined LEO Pharma Inc. as Vice President of Sales in July 2015.  Mr. Johnson is responsible for the enhancement and expansion of the efforts of the LEO U.S. sales team, in addition to managing the sales training and sales operations functions in the region.  

Mr. Johnson has over 25 years of experience in the pharmaceutical industry with an emphasis in sales management.  Prior to joining LEO, he held the position as Vice President, Sales - Respiratory at GlaxoSmithKline.  While at GlaxoSmithKline,  Mr. Johnson also held positions as Executive Director of the Influenza Franchise, Regional Sales Vice President of General Pharma, and Product Manager in the Diabetes Franchise.  Prior to joining the pharmaceutical industry, he played professional baseball for a total of 10 years with the Boston Red Sox and Houston Astros.

Johnson holds a Bachelor of Science in Business Administration from Bryant University in Rhode Island and a Masters of Business Administration from Duke University in Durham, North Carolina.


Domenic Verroca, VP, Patient Market Access & Public Affairs

Domenic Verroca, Ph.D. joined LEO Pharma U.S. as Vice President of Market Access & Public Affairs in July 2015.

Mr. Verroca joins LEO Pharma after serving as Vice President of Market Access at Galderma. Prior to Galderma, Verroca worked at Sanofi for over 11 years in positions of increasing responsibility. His last position at Sanofi was as Vice President of U.S. Market Access – a position he held for over 6 years. He also worked for Pharmacia and Johnson & Johnson Health Care Systems.

Verroca holds a B.A. in Economics and Geography from Coventry University in England, a M.A. in International Affairs from Drew University and a Ph.D. in Management from the University of Pittsburgh.


Doreen V. Morgan, VP, U.S. Regulatory Affairs

Dr. Doreen V. Morgan joined LEO Pharma as VP, U.S. Regulatory Affairs in October 2015.   Dr.  Morgan leads the U.S. Regulatory team, ensures that U.S. regulatory strategies and initiatives support successful U.S. launches for LEO U.S. Region, and oversees regulatory operations and cross functional processes to facilitate strong collaboration between the U.S. organization and Regulatory Affairs in LEO Pharma in Ballerup, Copenhagen.
Dr. Morgan has over 25 years of experience in the pharmaceutical industry which includes extensive knowledge of U.S. FDA regulatory requirements, global regulatory strategy and regulatory leadership of global trials (US, EU, JP) as well as a strong track record of interdisciplinary team building skills and experience from managing cross functional teams within a matrix organization.
Prior to joining LEO, she held the position of Executive Director of Regulatory Affairs at Daiichi Sankyo Pharma Development for over eight years.   At Daiichi Sankyo, she led the global regulatory strategy for a Factor Xa Inhibitor product in the three major regions (US, EU and Japan) supporting two indications for registration studies with over 29,000 subjects.  Prior to Daiichi, Dr. Morgan worked at Forest Laboratories as the Senior Director of Regulatory Affairs, held the position of Director of U.S. Regulatory at Knoll Pharmaceutical Company and positions of increasing responsibility at Hoffman-La Roche.  
Dr. Morgan holds a Doctor of Pharmacy and a Masters of Science in Clinical Pharmacy from St. John’s University.

Kylie O'Keefe, Director, Strategic Marketing

Kylie O'Keefe joined the LEO U.S. Region as the Director of Strategic Marketing in January 2016.  
Ms. O'Keefe provides strategic oversight for the Picato® U.S. Must Win Battle (MWB), one of the four global Must Win Battle initiatives for LEO Pharma.  She also communicates the progress of projects to the Global Picato U.S. MWB Steering Committee.   Ms. O'Keefe is responsible for the U.S. forecasting, long-term planning, partnering with business development and process control and planning.    
Ms. O'Keefe started her career with LEO Pharma Australia in 2009 as a Sales Representative and was promoted into the role of Product Manager during her four year tenure.  In 2012, she was appointed to the position of Global External Relations Manager at LEO Pharma in Denmark.  In her career at LEO, she has moved from positions of increasing responsibility as Global Patient Solutions Manager AK to Head of Global Business and Launch Planning AK.  Prior to joining LEO Pharma, Kylie worked for Peplin Ltd. and was a member of the Clinical Operations team.  
Ms. O'Keefe holds a Bachelor of Biotechnology Innovation from Queensland University of Technology, Brisbane, Australia. 

Tiffany L. Christian, Director, Legal

Tiffany L. Christian joined LEO Pharma in August  2013 as Associate Director, Legal and was promoted to the position of Director, Legal in January 2015.  

As the Director of Legal, Ms. Christian is responsible for managing and overseeing all legal activities for the U.S. Region and she functions as the chief legal officer for LEO Pharma U.S. Ms. Christian provides commercial and regulatory support on the company’s marketed products, as well as support on issues relating to the company’s drug development programs and pipelines in the U.S.  In addition, Ms. Christian provides guidance and training to various internal functional areas on FDA laws and regulations, consumer protections laws, and other relevant laws and regulations governing the commercialization of pharmaceutical products in the U.S. 

Prior to joining LEO Pharma, Ms. Christian held the position of Counsel, Pharmaceuticals at Warner Chilcott  (U.S.) LLC.  While at Warner Chilcott, she provided general counsel and advice to the specialty pharmaceutical company concerning matters affecting the company’s U.S. operations, with a focus on the advertising and promotion of its products.  Prior to Warner Chilcott, Ms. Christian was a Commercial Litigation/Product Liability Associate at DLA Piper LLP (U.S.) and before that at Sills Cummis & Gross P.C. 

Ms. Christian holds a Juris Doctor from Georgetown University Law Center in Washington DC and a Bachelor of Arts from Cornell University in Ithaca, New York.   


Lars Bukhave Rasmussen, Vice President, Patient Solutions

Lars Bukhave Rasmussen joined LEO U.S. as Vice President of Patient Solutions in August 2016.  In his role Mr. Rasmussen is responsible for the development and execution of marketing strategies for both the Psoriasis and Actinic Keratosis (AK) franchises and the PRISM organization (Patient Relations, Insights and Stakeholder Engagement and Quality Care), in addition to championing the company’s patient-centric philosophy and business model. 

Mr. Rassmussen has been with LEO Pharma A/S since 2006.  His early LEO experience includes roles in Business Development and Corporate Strategy & Planning.  In addition, he served on the strategic U.S. Must Win Battle program as a U.S. Liaison to LEO Pharma Corporate in 2011. 
In 2012 Mr. Rassmussen joined the Global Patient Solutions Thrombosis team as head of the innohep® franchise and served in that role until being promoted to Vice President, Project Management within the R&D organization in 2015.  Prior to joining LEO U.S, he served as Vice President in Global Product Supply, heading up the LEO Pharma GLOBE Program to implement a new business technology platform for the entire LEO organization.
Mr. Rassmussen is a Doctor of Veterinary Medicine, holds a Bachelor of Business Administration (Accounting), and in 2015 earned an Executive Master of Business Administration from Henley Business School in the United Kingdom.